Trial
NCT03682497
Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Heart Failure
Intervention
AZD9977
Why stopped
Attendance at study sites carries risk of COVID-19 infection. Non-attendance at planned study site visits has unacceptable study related patient safety risk.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-01